Opinion|Videos|July 8, 2024
Frontline BTKi Selection
Key opinion leaders examine the use of continuous Bruton's tyrosine kinase inhibitor therapy in front-line treatment, strategies for sequencing therapies, and the potential incorporation of obinutuzumab into treatment regimens.
Advertisement
Episodes in this series
- Dr Lamanna: When considering continuous BTKi therapy in the front-line setting, how do you select among available treatment options?
- How do you select patients for acala vs zanu?
- In which patients would you consider the addition of obinutuzumab?
- Dr Danilov: How important is long-term efficacy and safety data when making informed treatment decisions and how may these data shape your overall treatment approach?
- Dr Coombs asks about Frontline use??
- ELEVATE-TN – 6-yr follow up (Sharman, et al. ASH 2023. Abstract 636)
- SEQUOIA – Extended Follow-up (Munir, et al. Hemasphere 2023)
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 that may shake up the CLL treatment paradigm.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC
4
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
5